Galapagos NV has agreed a drug discovery collaboration with Bristol University to develop treatments for chronic pain associated with diabetes.
Galapagos’ UK service division BioFocus will provide hit-to-lead and lead optimisation services for a Wellcome Trust funded programme at Bristol. Total contract value for Galapagos could exceed €3.3 million in research fees over two years.
This work is supported by a Seeding Drug Discovery Award from Wellcome, to a team of researchers...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.